<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144534</url>
  </required_header>
  <id_info>
    <org_study_id>MRA215JP</org_study_id>
    <nct_id>NCT00144534</nct_id>
  </id_info>
  <brief_title>Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP</brief_title>
  <official_title>An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <brief_summary>
    <textblock>
      This is an open-label, extension, Phase III study to evaluate the long-term safety and
      efficacy of MRA in patients with RA who participated in Study MRA213JP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy:the frequency of amelioration of at least 20% in terms of the ACR criteria</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and degree (severity and seriousness) of adverse events and adverse drug reactions</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of the serum MRA concentration</measure>
    <time_frame>0W,4W,8W,12W,LOBS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy:time courses of DAS28, frequencies of amelioration of at least 20%, 50%, and 70% in terms of the ACR criteria, each item in the ACR core set</measure>
    <time_frame>0W,4W,8W,12W,LOBS</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRA (Tocilizumab)</intervention_name>
    <description>8mg/kg/4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Either MRA or placebo was administered at least 3 times in the preceding study, and
             there were confirmed to be no problems with respect to safety.

          -  In the case of Patients whose participation in the current study was judged to be
             inappropriate because of problems in the preceding study with respect to safety, these
             Patients must have been in the methotrexate dose group in the preceding study.

        Exclusion criteria

          -  Administered drugs such as infliximab, etanercept, and leflunomide within 12 weeks
             before administration of the study drug

          -  Evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration
             of the study drug

          -  Have not been registered by 3 months after the full code-breaking of the preceding
             study

          -  Were administered plasma exchange therapy between initiation of the preceding study
             and the initial administration in the current study

          -  Treated surgically (except for local surgery) within 4 weeks before administration of
             the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takahiro Kakehi</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>December 21, 2009</last_update_submitted>
  <last_update_submitted_qc>December 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical</name_title>
    <organization>Chugai Pharmaceutical</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

